Eli Lilly rolls out new Zepbound vial versions on LillyDirect
by
Contributor since / Followers
Contributor since / Followers
1 month ago
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) announced Tuesday it expanded its weight loss drug offerings, launching new 7.5 mg and 10 mg single-dose vial formats of its popular weight loss therapy Zepbound (tirzepatide) at $499 through its direct-to-consumer website, LillyDirect.
That indicates nearly